Design, synthesis and evaluation of XZH-5 analogues as STAT3 inhibitors

Bioorg Med Chem. 2015 Mar 15;23(6):1348-55. doi: 10.1016/j.bmc.2015.01.025. Epub 2015 Jan 22.

Abstract

Inhibition of the signaling pathways of signal transducer and activator of transcription 3 (STAT 3) has shown to be a promising strategy to combat cancer. In this paper we report the design, synthesis and evaluation of a novel class of small molecule inhibitors, that is, XZH-5 and its analogues, as promising leads for further development of STAT3 inhibitors. Preliminary SARs was established for XZH-5 and its derivatives; and the binding modes were predicted by molecular docking. Lead compounds with IC50 as low as 6.5μM in breast cancer cell lines and 7.6μM in pancreatic cancer cell lines were identified.

Keywords: Inhibitor; Molecular docking; SARs; SH2; STAT3; Small organic molecule.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Proliferation / drug effects
  • Dose-Response Relationship, Drug
  • Drug Design*
  • Histidine / analogs & derivatives*
  • Histidine / chemical synthesis
  • Histidine / chemistry
  • Histidine / pharmacology
  • Humans
  • Molecular Structure
  • Phenylurea Compounds / chemical synthesis*
  • Phenylurea Compounds / chemistry
  • Phenylurea Compounds / pharmacology*
  • STAT3 Transcription Factor / antagonists & inhibitors*
  • STAT3 Transcription Factor / metabolism
  • Structure-Activity Relationship
  • Tumor Cells, Cultured

Substances

  • Phenylurea Compounds
  • STAT3 Transcription Factor
  • STAT3 protein, human
  • XZH-5 compound
  • Histidine